The mouse model studies were done for a omomyc-CPP fusion. The object there was to show that PYC's CPP is superior to other 'transporter' compounds. It isn't clear to me from the ASX announcements what the controls were. Animal models for omomyc studies should be well established by now.
The studies done so far on PYC's own myc-inhibitors have been in vitro. Presumably, the company is working on finalising the animal model for their proprietary myc-inhibitors.
Unless there are new facts to change my mind, I'm supportive of PYC taking the time to do the study design and animal trials right. The reason for this (as all of you know) is that there is a huge prize for a company that can have a CPP-drug cargo fusion which has established proof-of-concept. There may be a chance of deal with animal trial results in hand.
In terms of Christmas, let it come in June I say! 2-4c range for the share price is entirely feasible if they have something of note to announce.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)